Reviewing Rani Therapeutics (NASDAQ:RANI) & AquaBounty Technologies (NASDAQ:AQB)
by Mitch Edgeman · The Markets DailyAquaBounty Technologies (NASDAQ:AQB – Get Free Report) and Rani Therapeutics (NASDAQ:RANI – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.
Earnings and Valuation
This table compares AquaBounty Technologies and Rani Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| AquaBounty Technologies | $2.47 million | 2.40 | -$18.49 million | ($0.82) | -1.40 |
| Rani Therapeutics | $1.63 million | 74.00 | -$29.67 million | ($0.27) | -3.20 |
AquaBounty Technologies has higher revenue and earnings than Rani Therapeutics. Rani Therapeutics is trading at a lower price-to-earnings ratio than AquaBounty Technologies, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares AquaBounty Technologies and Rani Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| AquaBounty Technologies | N/A | -147.07% | -28.73% |
| Rani Therapeutics | N/A | -104.60% | -65.17% |
Analyst Recommendations
This is a breakdown of recent ratings and recommmendations for AquaBounty Technologies and Rani Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| AquaBounty Technologies | 1 | 0 | 0 | 0 | 1.00 |
| Rani Therapeutics | 1 | 0 | 4 | 1 | 2.83 |
Rani Therapeutics has a consensus target price of $8.75, indicating a potential upside of 911.21%. Given Rani Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Rani Therapeutics is more favorable than AquaBounty Technologies.
Institutional & Insider Ownership
8.9% of AquaBounty Technologies shares are owned by institutional investors. Comparatively, 30.2% of Rani Therapeutics shares are owned by institutional investors. 1.0% of AquaBounty Technologies shares are owned by company insiders. Comparatively, 26.7% of Rani Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Risk & Volatility
AquaBounty Technologies has a beta of 1.45, meaning that its share price is 45% more volatile than the S&P 500. Comparatively, Rani Therapeutics has a beta of 0.69, meaning that its share price is 31% less volatile than the S&P 500.
Summary
Rani Therapeutics beats AquaBounty Technologies on 9 of the 14 factors compared between the two stocks.
About AquaBounty Technologies
AquaBounty Technologies, Inc., a biotechnology company, operates in the aquaculture industry in the United States and Canada. The company engages in genetic, genomic, and fish health and nutrition research activities. It also operates salmon farms using proprietary technology. In addition, the company offers AquAdvantage Salmon, a genetically engineered Atlantic salmon for human consumption; and sells conventional Atlantic salmon, salmon eggs, fry, and byproducts. The company was formerly known as Aqua Bounty Farms, Inc. and changed its name to AquaBounty Technologies, Inc. in June 2004. AquaBounty Technologies, Inc. was incorporated in 1991 and is headquartered in Harvard, Massachusetts.
About Rani Therapeutics
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.